BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22750758)

  • 1. Inflammatory markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapy.
    Chua TC; Chong CH; Liauw W; Zhao J; Morris DL
    Ann Surg; 2012 Aug; 256(2):342-9. PubMed ID: 22750758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
    Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
    Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
    Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
    In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei.
    Sørensen O; Flatmark K; Reed W; Wiig JN; Dueland S; Giercksky KE; Larsen SG
    Eur J Surg Oncol; 2012 Oct; 38(10):969-76. PubMed ID: 22763244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL
    J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms.
    Yan TD; Links M; Xu ZY; Kam PC; Glenn D; Morris DL
    Br J Surg; 2006 Oct; 93(10):1270-6. PubMed ID: 16838392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
    Baratti D; Kusamura S; Nonaka D; Cabras AD; Laterza B; Deraco M
    Ann Surg; 2009 Feb; 249(2):243-9. PubMed ID: 19212177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC.
    Ross A; Sardi A; Nieroda C; Merriman B; Gushchin V
    Eur J Surg Oncol; 2010 Aug; 36(8):772-6. PubMed ID: 20561764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
    Sugarbaker PH
    Eur J Surg Oncol; 2001 Apr; 27(3):239-43. PubMed ID: 11373099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm.
    Murphy EM; Sexton R; Moran BJ
    Dis Colon Rectum; 2007 Jan; 50(1):37-42. PubMed ID: 17115339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin.
    Youssef H; Newman C; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Dis Colon Rectum; 2011 Mar; 54(3):293-9. PubMed ID: 21304299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA 19-9 to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with epithelial appendiceal mucinous neoplasms and peritoneal dissemination undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
    Kozman MA; Fisher OM; Rebolledo BJ; Valle SJ; Alzahrani N; Liauw W; Morris DL
    Eur J Surg Oncol; 2017 Dec; 43(12):2299-2307. PubMed ID: 28993033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis.
    El Halabi H; Gushchin V; Francis J; Athas N; Macdonald R; Nieroda C; Studeman K; Sardi A
    Ann Surg Oncol; 2012 Jan; 19(1):110-4. PubMed ID: 21701929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.
    Taflampas P; Dayal S; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2014 May; 40(5):515-520. PubMed ID: 24462284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Kusamura S; Baratti D; Hutanu I; Gavazzi C; Morelli D; Iusco DR; Grassi A; Bonomi S; Virzì S; Haeusler E; Deraco M
    Eur J Surg Oncol; 2015 Aug; 41(8):1097-105. PubMed ID: 26026742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?
    Sugarbaker PH
    Lancet Oncol; 2006 Jan; 7(1):69-76. PubMed ID: 16389186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms.
    Choe JH; Overman MJ; Fournier KF; Royal RE; Ohinata A; Rafeeq S; Beaty K; Phillips JK; Wolff RA; Mansfield PF; Eng C
    Ann Surg Oncol; 2015 Aug; 22(8):2578-84. PubMed ID: 25582740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of pseudomyxoma peritonei of appendiceal origin--surgical resection and intraperitoneal chemotherapy.
    Hosch WP; Rudi J; Stremmel W
    Z Gastroenterol; 1999 Jul; 37(7):615-22. PubMed ID: 10458011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.
    Vaira M; Cioppa T; D'Amico S; de Marco G; D'Alessandro M; Fiorentini G; De Simone M
    In Vivo; 2010; 24(1):79-84. PubMed ID: 20133981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.